SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NVS: Novartis AG -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (4)12/5/2000 7:50:52 PM
From: Arthur Radley  Read Replies (1) | Respond to of 116
 
This is the part I like..."``This is not a miracle drug,'' he said, but it is a model for future cancer study
because it targets the cause of the disease without damaging other cells."

This could be the silver bullet that scientist have been looking for. The write-up in the local paper(Houston Chronicle) was the most exciting article I've read in a long time. The case studies mentioned were fantastic.



To: Starlight who wrote (4)1/1/2001 7:34:18 PM
From: Smartypts  Read Replies (1) | Respond to of 116
 
Liz How does this differ from Spot Radiation? Are Leukemia patients able to undergo the type that specifically targets the tumor? Not very familiar w/Leukemia but like the stock.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News